$21.60
1.23% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US0008991046
Symbol
ADMA
Sector
Industry

ADMA Biologics, Inc. Stock price

$21.60
+1.15 5.62% 1M
+2.93 15.69% 6M
+4.45 25.95% YTD
+10.82 100.37% 1Y
+18.68 639.73% 5Y
+13.03 152.04% 10Y
+13.05 152.63% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.27 1.23%
ISIN
US0008991046
Symbol
ADMA
Sector
Industry

Key metrics

Market capitalization $5.16b
Enterprise Value $5.16b
P/E (TTM) P/E ratio 25.71
EV/FCF (TTM) EV/FCF 57.13
EV/Sales (TTM) EV/Sales 11.23
P/S ratio (TTM) P/S ratio 11.23
P/B ratio (TTM) P/B ratio 13.80
Revenue growth (TTM) Revenue growth 62.23%
Revenue (TTM) Revenue $459.38m
EBIT (operating result TTM) EBIT $150.80m
Free Cash Flow (TTM) Free Cash Flow $90.28m
Cash position $71.63m
EPS (TTM) EPS $0.84
P/E forward 33.58
P/S forward 10.15
EV/Sales forward 10.15
Short interest 7.36%
Show more

Is ADMA Biologics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

ADMA Biologics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a ADMA Biologics, Inc. forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a ADMA Biologics, Inc. forecast:

Buy
75%
Hold
25%

Financial data from ADMA Biologics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
459 459
62% 62%
100%
- Direct Costs 218 218
27% 27%
47%
242 242
117% 117%
53%
- Selling and Administrative Expenses 87 87
37% 37%
19%
- Research and Development Expense 2.19 2.19
24% 24%
0%
151 151
702% 702%
33%
- Depreciation and Amortization 0.22 0.22
70% 70%
0%
EBIT (Operating Income) EBIT 151 151
733% 733%
33%
Net Profit 207 207
5,780% 5,780%
45%

In millions USD.

Don't miss a Thing! We will send you all news about ADMA Biologics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ADMA Biologics, Inc. Stock News

Neutral
Investors Business Daily
25 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
Seeking Alpha
about one month ago
ADMA Biologics has demonstrated significant revenue growth, margin expansion, and profitability, leading to a 1,314% increase in share price since 2021. The company's Q1 performance showed a 40% YoY revenue increase, strong demand for ASCENIV, and improved gross profit margins. ADMA's financial health is robust, with $171M in cash and receivables, reduced debt costs, and a new $500M share repur...
Neutral
Seeking Alpha
about one month ago
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - Founder, Director, President and Chief Executive Officer Brad Tade - Chief Financial Officer and Treasurer Conference Call Participants Anthony Petrone - Mizuho Group Rick Miller - Cantor Fitz...
More ADMA Biologics, Inc. News

Company Profile

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Head office United States
CEO Adam Grossman
Employees 685
Founded 2004
Website www.admabiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today